Fig. 5
From: Preclinical comparison of prolgolimab, pembrolizumab and nivolumab
Activation of antibody-dependent cellular phagocytosis (ADCP) by prolgolimab, pembrolizumab and nivolumab. (A) Evaluation of the antibody binding to FcγRIa in a reporter bioassay. PBMCs were pre-activated with SEB. (A, left) Average differences in luminescence in the presence of 10 ng/ml and in the absence of the test antibodies (based on the results of 3 experiments). Data are shown as the mean ± SD. Statistical analyses were performed using the two-tailed paired Student’s t-tests. (A, right) A representative plot of luminescence intensity versus antibody concentration. (B) ADCP with monocyte-derived macrophages and PD-1 expressing cells. Negative control—trastuzumab (anti-HER2 antibody). (B, left) Average ADCP values in the presence of 400 ng/ml of the test antibodies from the results of 5 experiments. Data are shown as the mean ± SD. Statistical analyses were performed using the two-tailed paired Student’s t-tests. (B, right) A representative graph of the proportion of macrophages that phagocytized target cells versus antibody concentration. Control anti-PD-1 IgG1 – IgG1 with pembrolizumab’s variable domains.
